Dana Pokorná

Dana Pokorná

Auto-generated profile, based on publicly available information

Dana Pokorná

Institute of Hematology and Blood Transfusion, Department of Experimental Virology, U Nemocnice 1, 12820 Prague 2, Czech Republic

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2009 in Vaccine
Verified
Journal Article
Closed access
DPDana Pokorná
Dana Pokorná
IPIngrid Polakova
Ingrid Polakova
MKMartina Kindlová
Martina Kindlová
MDMartina Dušková
Martina Dušková
VLViera Ludvíková
Viera Ludvíková
MSMichal Smahel
Michal Smahel

5 May 2004 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
MSMichal Smahel
Michal Smahel
DPDana Pokorná
Dana Pokorná
JMJana Macková
Jana Macková
JVJosef Vlasak
Josef Vlasak

11 February 2005 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
DPDana Pokorná
Dana Pokorná
JMJana Macková
Jana Macková
MDMartina Dušková
Martina Dušková
ŠRŠimon Rittich
Šimon Rittich
VLViera Ludvíková
Viera Ludvíková
MSMichal Smahel
Michal Smahel

1 October 2005 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
DPDana Pokorna
Dana Pokorna
NCNoemi Cerovska
Noemi Cerovska
MSMichal Smahel
Michal Smahel
TMTomas Moravec
Tomas Moravec
VLViera Ludvikova
Viera Ludvikova
JVJiri Veleminsky
Jiri Veleminsky
Vaccine strategies for the treatment of human papillomavirus-induced cervical cancer are based mainly on the human papillomavirus 16 E7 (HPV16 E7) oncoprotein. The immunogenicity of the E7 gene has been enhanced by its fusion to many different genes. Here, we linked a short sequence coding for the E7 peptide (aa 44-60) containing immunodominant epitopes for B and T cells to the 3' end of the gene coding for the whole coat protein (CP) of the poty-virus, potato virus A (PVA), and its deleted form (CPdel) with a short C-terminal deletion of 5 amino acids (LGVKG). CP-E7 and CPdel-E7 fusion proteins, just like CP alone, spontaneously assembled into virus-like particles in both procaryotic and eucaryotic cells. The CP-E7 and CPdel-E7 fusion genes induced slightly stronger E7-specific cytotoxic T-lymphocyte responses than the whole E7 gene, although they were still lower than those elicited by the previously constructed fusion gene, Sig/E7GGG/LAMP-1. The E7- and CP-specific antibody responses were not detected in mice vaccinated with CP-E7 and CPdel-E7 fusion genes. The CP-E7 and CPdel-E7 fusion genes protected mice against the development of tumors induced by TC-1 cells producing the E7 antigen and were also effective in the therapeutic setting, i.e. when the vaccination was performed after tumor cell administration. Their antitumor effect was comparable to those of the whole E7 gene and Sig/E7GGG/LAMP-1 fusion gene. There was no relevant difference between immune responses elicited by CP-E7 and CPdel-E7 DNA vaccination.